Parnell Pharmaceuticals Holdings Ltd
PARNF · OTC
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $34 | $30 | $29 | $27 |
| % Growth | 13.9% | 3.5% | 9.2% | – |
| Cost of Goods Sold | $15 | $12 | $12 | $11 |
| Gross Profit | $19 | $18 | $17 | $16 |
| % Margin | 56.4% | 58.4% | 60% | 58.5% |
| R&D Expenses | $3 | $2 | $1 | $1 |
| G&A Expenses | $9 | $7 | $8 | $6 |
| SG&A Expenses | $15 | $14 | $16 | $12 |
| Sales & Mktg Exp. | $6 | $7 | $6 | $5 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $18 | $21 | $17 | $12 |
| Operating Income | $1 | $4 | $1 | $3 |
| % Margin | 3.9% | 12.6% | 4.7% | 9.8% |
| Other Income/Exp. Net | -$3 | -$17 | -$7 | -$3 |
| Pre-Tax Income | -$1 | -$15 | -$7 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$15 | -$7 | $0 |
| % Margin | -4.2% | -50.2% | -24.8% | 0.5% |
| EPS | -0.049 | -0.81 | -0.4 | 0.007 |
| % Growth | 94% | -102.5% | -5,680.4% | – |
| EPS Diluted | -0.049 | -0.81 | -0.4 | 0.007 |
| Weighted Avg Shares Out | 29 | 19 | 18 | 18 |
| Weighted Avg Shares Out Dil | 29 | 19 | 18 | 18 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8 | $12 | $7 | $0 |
| Interest Expense | $0 | $0 | $0 | $6 |
| Depreciation & Amortization | $2 | $0 | $1 | $3 |
| EBITDA | $6 | $4 | $2 | $5 |
| % Margin | 17.6% | 14.1% | 8.3% | 19.8% |